Luis Raez: Clinical and Economic Outcomes for Advanced NSCLC Patients in Trials After Liquid Biopsy
Journal of Managed Care and Specialty Pharmacy.
Authors: Julie A. Wiedower, Shaun P. Forbes, L. Jill Tsai, Jiemin Liao and Luis E. Raez.
“Clinical trials benefit patients and divert specialty drug costs, but barriers to enrollment include access, costs and coverage, and delays from tissue genomic tumor profiling. Our study shows that patients with non–small cell lung cancer enrolling in clinical trials following liquid biopsy had improved survival without increasing costs compared with matched controls. Specialty
drug management should include coverage for testing likely to guide the appropriate use of therapies, which improves survival and drives clinical trial enrollment, also improving survival.”
Dr. Luis Raez is the Medical Director and Chief Scientific Officer at Memorial Cancer Institute, part of Memorial Healthcare System. He specializes in treating lung and head and neck cancers and leads the Thoracic Oncology Program as Director. Dr. Raez is also a clinical professor of medicine at Florida International University (FIU), a research professor at Florida Atlantic University (FAU), and a visiting professor of medicine at Cayetano Heredia University (UPCH) in Peru.